Canadian cannabis stocks surged sharply Tuesday afternoon after The Associated Press reported that the U.S. Drug Enforcement Administration intends to propose reclassifying marijuana as a less dangerous drug under federal law. The news was widely viewed by investors as a potentially significant step toward easing the federal legal restrictions that have long constrained the U.S. cannabis industry.
Market activity was immediate and dramatic. Canopy Growth Corp. jumped 49% on the report, while Aurora Cannabis Inc. and Tilray Brands Inc. rose roughly 32% and 39%, respectively. These moves reflected investor optimism that a federal reclassification could reduce legal and regulatory risk for companies with U.S. exposure and improve the long-term outlook for the cannabis sector.
The Associated Press, citing five sources familiar with the matter, said the DEA’s proposal would formally recognize the medical uses of cannabis and acknowledge that it carries less potential for abuse than drugs currently placed in the most restrictive federal category. According to that reporting, the change would move marijuana from Schedule I to Schedule III of the Controlled Substances Act. Under current federal scheduling, marijuana is categorized as Schedule I—the same classification as heroin and LSD—while Schedule III includes drugs such as ketamine and certain anabolic steroids.
It is important to stress that, as reported, reclassification would not equate to federal legalization for adult recreational use. Instead, it would alter the federal classification that governs how the substance is regulated at the national level. Any such reclassification reported by the AP would still require formal rulemaking and regulatory steps before it became final and enforceable.
Why this matters to investors and companies: federal scheduling affects a range of practical issues. A lower scheduling designation could reduce some criminal and regulatory exposure for companies and individuals involved in medical cannabis, potentially influence access to banking and financial services, and ease restrictions on research. Those potential improvements could make cannabis companies more attractive to institutional investors and reduce perceived operational risk for firms that have U.S. operations or plans to enter U.S. markets. Market reactions on the day of the report reflected traders pricing in those possibilities.
Even with the reported proposal, substantial legal and commercial obstacles would remain. State-level regulations, varying medical and recreational market rules across states, and ongoing debates about tax treatment, licensing, and interstate commerce would continue to shape the industry’s outlook. In addition, any federal rulemaking process can take time and is subject to public comment, revision, and potential legal challenges. As a result, while a reclassification could represent a meaningful regulatory shift, the transition and its ultimate effects for companies and investors would likely unfold over months or longer.
For Canadian cannabis firms that have pursued U.S. opportunities or that rely on cross-border capital flows, the prospect of a lower federal scheduling could reduce a key source of uncertainty. That said, investors should remain aware that market volatility can be pronounced around regulatory headlines, and initial price moves may reflect short-term sentiment rather than long-term fundamentals.
Companies mentioned in this report: Canopy Growth Corp. (TSX:WEED), Aurora Cannabis Inc. (TSX:ACB), Tilray Brands Inc. (TSX:TLRY).
Newsletter
Get free MoneySense financial tips, news & advice in your inbox.
More about investing:
- Best ETFs in Canada
- Making sense of the markets
- The best dividend stocks in Canada
- Best online brokers in Canada